Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical  company   advancing non-hallucinogenic, psychedelic-derived neuroplastogens  for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders, including AUD,  today announced  an advancement of its IP portfolio with the publication in the United States of its patent application covering a novel combination of 3,4-methylenedioxymethamphetamine ("MDMA") and N-acylethanolamines, such as palmitoylethanolamide ("PEA"), in methods of treating post-traumatic stress disorder (PTSD), anxiety, and eating disorders. The U.S. patent application was published by the United States Patent and Trademark Office (USPTO).